Contact us  to learn more about
our Premium Content:  News alerts, weekly reports and conference planners


Other names: Promega | Promega Corporation
Related tests:


Stilla and Promega announce co-marketing agreement to offer complete digital PCR workflow solution (Stilla Technologies Press Release)
"Stilla Technologies, the multiplex digital PCR company, and Promega Corporation today announced a co-marketing agreement that combines sample preparation with the latest Maxwell® systems and digital PCR on the six-color naica® system. With this partnership, the companies will offer an optimized workflow for a wide range of applications including liquid biopsy, sentinel pathogen testing, infectious disease assays, overall cancer research and drug discovery."
Licensing / partnership
New study validates novel markers for detecting microsatellite instability in multiple cancers (BioSpace)
"Researchers from Johns Hopkins University have shown that a new panel of long mononucleotide repeats (LMR) might offer advantages over traditional microsatellite instability (MSI) detection methods in certain types of solid tumors. The study, published in the February issue of Journal of Molecular Diagnostics, is the first to use the PCR-based Promega Corporation LMR MSI Analysis System to detect MSI in endometrial, prostate and other cancers."
Clinical data
Promega launches OncoMate™ MSI Dx Analysis System in US (Promega Press Release)
"Promega Corporation today launched its OncoMate™ MSI Dx Analysis System (OncoMate™ MSI) in vitro diagnostic (IVD) in the US, giving oncologists and pathologists a new option to screen for Lynch syndrome in patients with colorectal cancer."
Launch US
OncoMate™ MSI
Promega and Henlius developing microsatellite instability companion diagnostic IVD kit for serplulimab in China (Promega Press Release)
"Shanghai Promega Biological Products Co., Ltd. and Shanghai Henlius Biotech, Inc. will develop and commercialize a microsatellite instability (MSI) companion diagnostic IVD kit to identify cancer patients likely to benefit from serplulimab, a novel anti-PD-1 monoclonal antibody (mAb) developed by Henlius for the potential treatment of microsatellite instability-high (MSI-H) solid tumors. The kit will be available to doctors in the Chinese Mainland to screen for MSI and inform immunotherapy options."
Licensing / partnership
FDA clears Promega OncoMate™ MSI Dx Analysis System (Promega Press Release)
"Oncologists and pathologists in the United States can now access a new in vitro diagnostic (IVD) test that screens for Lynch syndrome in patients with colorectal cancer. The OncoMate™ MSI Dx Analysis System (OncoMate™ MSI), developed by Promega, has been cleared by the US Food and Drug Administration (FDA) as an IVD medical device to determine microsatellite instability (MSI) status in colorectal cancer tumors. This is the industry's first and only PCR-based diagnostic kit for MSI characterization that is FDA-cleared for use in labs across the United States."
FDA event
OncoMate™ MSI
Promega, Exact Sciences partnering to help jumpstart colorectal cancer screenings (Promega Press Release)
"Get Your Rear in Gear - Madison is presented by Promega and Exact Sciences with the support of the Colon Cancer Coalition. This inaugural event is one of nearly 40 held annually across the country planned by local volunteers. Money raised will go to UW Carbone Cancer Center programs aimed at increasing colon cancer screening and early detection."
Licensing / partnership
Promega Developing OncoMate MSI Assay as Companion Diagnostic for Endometrial Cancer Drug Candidate from Incyte (Businesswire)
"Promega Corporation announced today its intent to develop the Promega OncoMate™ microsatellite instability (MSI) Assay as a companion diagnostic test for retifanlimab, Incyte’s anti-PD-1 drug candidate, in endometrial cancer. Financial terms of the global agreement with Incyte were not disclosed...Promega and Incyte intend to work together in the future to develop the Promega OncoMate MSI Assay as a companion diagnostic in other markets."
OncoMate™ MSI
Zynyz (retifanlimab)